10-Q: Absci Corporation Reports Q2 2024 Results: Revenue Declines Amidst Continued R&D Investment

Absci Corporation's Q2 2024 results show a decrease in technology development revenue compared to the same period last year, while the company continues to invest in research and development.

Summary

• Absci Corporation reported a net loss of $24.8 million for the three months ended June 30, 2024, and $46.7 million for the six months ended June 30, 2024.
• Technology development revenue decreased to $1.3 million for the three months ended June 30, 2024, and $2.2 million for the six months ended June 30, 2024, compared to $3.4 million and $4.6 million for the same periods in 2023, respectively.
• Research and development expenses increased by 26% for the three months ended June 30, 2024, and 11% for the six months ended June 30, 2024, compared to the same periods in 2023.
• The company had cash, cash equivalents, and short-term investments totaling $145.2 million as of June 30, 2024.
• Absci has identified three wholly-owned internal pipeline programs focusing on cytokine biology, with plans to initiate Phase 1 clinical studies for ABS-101 in early 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in R&D and secured funding, the decline in revenue and continued losses raise concerns. The sentiment is neutral to slightly negative due to the financial performance.

Positives

• The company successfully raised $80.8 million through a public offering of common stock.
• Absci continues to advance its internal pipeline programs, with ABS-101 expected to enter Phase 1 clinical trials in early 2025.
• The company maintains a strong cash position with $145.2 million in cash, cash equivalents, and short-term investments.
• Absci is actively engaged with 24 partners and has 16 active programs, indicating continued market interest in its platform.

Negatives

• Technology development revenue experienced a significant decrease compared to the previous year.
• The company continues to incur net losses, with an accumulated deficit of $453.2 million as of June 30, 2024.
• Operating expenses remain high, particularly in research and development, which may impact profitability in the near term.

Risks

• The company's future financial performance is dependent on the successful development and commercialization of drug candidates, which is subject to significant risks and uncertainties.
• Absci's business model relies on partnerships, and there is no guarantee that partners will advance drug candidates or license the company's technology.
• The company faces competition from other biotechnology companies, which could impact its ability to secure partnerships and generate revenue.
• The company may need to raise additional capital in the future, which could dilute existing shareholders' ownership.

Future Outlook

Absci expects to continue to incur significant expenses as it develops its internal pipeline, engages in research and development, and expands its platform capabilities. The company anticipates revenue growth as it grants licenses to partners and as partnered programs advance through clinical development and commercialization. They plan to initiate Phase 1 clinical studies for ABS-101 in early 2025.

Management Comments

• The company aims to assemble economic interests in a diversified portfolio of partnered pipeline assets of drug candidates across diverse indications.
• Absci also aims to create its own internal pipeline comprising drug candidates across diverse indications.
• The company balances the portfolio between partnered programs that broaden its reach into diverse indications with a variety of economic structures and internal programs for which it has more control and the potential for partnerships or asset sales that provide greater economic returns.

Industry Context

Absci operates in the competitive biotechnology sector, focusing on AI-driven drug discovery. The company's approach to integrating AI with wet lab technologies is aimed at accelerating the development of biologics, a growing area of the pharmaceutical industry. The company is competing with other companies developing AI platforms for drug discovery and those developing similar therapeutics.

Comparison to Industry Standards

• Absci's approach to drug discovery, using AI to optimize multiple drug characteristics, is similar to other companies in the AI-driven drug discovery space, such as Recursion Pharmaceuticals and Exscientia.
• The company's goal of shortening preclinical development timelines from 5-7 years to 18-24 months is ambitious but aligns with the industry's push for faster drug development.
• The company's focus on biologics, particularly antibody-based therapeutics, is consistent with a major trend in the pharmaceutical industry.
• The company's internal pipeline programs, such as ABS-101 targeting TL1A, are competing with clinical stage assets being developed by larger pharmaceutical companies like Merck, Roche, and Sanofi.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and continued losses, but encouraged by the company's R&D progress and recent capital raise.
• Employees may be impacted by the company's financial performance, but also benefit from the company's growth and development.
• Partners may be affected by the company's ability to deliver on its technology and meet project milestones.
• Customers may benefit from the company's advancements in drug discovery and development.

Next Steps

• The company plans to continue developing its internal pipeline of drug candidates.
• Absci intends to advance ABS-101 into Phase 1 clinical studies in early 2025.
• The company will continue to seek new partnerships and expand existing relationships.
• Absci will continue to invest in research and development to enhance its platform capabilities.

Key Dates

Keywords

AI drug creation, biologics, generative AI, antibody therapeutics, drug discovery, preclinical development, clinical trials, technology development, research and development, partnerships